Utility of ROMA algorithm in assessing the aggressive potential of ovarian tumors during pregnancy by Munteanuˡ, Igor & Sârbu, Zinaida
UTILITY OF ROMA ALGORITHM IN ASSESSING THE AGGRESSIVE POTENTIAL OF 
OVARIAN TUMORS DURING PREGNANCY
Igor Munteanuˡ, Zinaida Sârbuˡ
ˡDepartment of Obstetrics and gynecology, Nicolae Testemitanu State University of Medicine and Pharmacy, 
Chisinau, Republic of Moldova 
Results
Preoperatively for each case, the serological results of the tumor markers were computer-modulated.
Criteria for assessing the prognostic power for ROMA score served the histological result of the fragment
removed intraoperatively.
To assess the sensitivity and specificity of ROMA algorithm with estimation of the prognostic power of
aggressive tumor potential, borderline ovarian tumors were considered as potentially malignant.
The sensitivity and specificity of the ROMA algorithm in this research is almost similar to the results
presented in literature: ROMA- sensitivity-87%; specificity-70%.
In the structure of the ovarian formations that included the histological analysis of n = 26 anatomosurgical
pieces, we confirmed: 10 cases - 38% simple or mixed seromucinous cystadenomas; 5 cases - 19% of
ovarian teratomas with embryonic tissue content - mainly hair, elements of cartilaginous tissue, neuronal
and adipose tissue; 4 cases - 16% being functional cysts such as thecalutein cysts and yellow body ovarian
cysts; 3 cases - 12% endometrial cysts were detected; also2 cases - 9% were borderline tumors and only
one case constituting - 3% of the total group of ovarian formations analyzed was malignant sex-
cord stromal tumor with Sertoli-Leydig cells; and one case - 3% of melanoma with systemic metastases
including ovarian.
Purpose
Familiarizing practitioners with the adjuvant opportunities of developed diagnostic tools
to optimize the preoperative differential diagnosis of ovarian tumors during
pregnancy.
Material and methods
We conducted a cross-sectional, prospective study. The paper reflects the
analysis of the results obtained in 26 pregnant women with ovarian cysts
detected during pregnancy, who subsequently benefited from surgical
treatment during the period 2016-2019.
The following specific laboratory data were analyzed in the study:
Tumor markers
Tumor markers are useful both in the diagnosis of neoplastic processes, for
assessing the progress of treatment and clinical surveillance of patients
who have received antitumor treatment [2].
CA-125 (cancer antigen 125)
CA-125 is a mucoglycoprotein synthesized mainly by tumor cells, but we
will mention that this tumor marker is synthesized in considerable
quantities and in the embryonic coelomic epithelium, so the importance
of this oncomarker in the first trimester of pregnancy is limited, with
considerable increase of its sensitivity and specificity in the second and
third trimesters of pregnancy [1], [18].
The threshold value of CA-125 during pregnancy, according to numerous
studies, is 35U / ml with limits of variations in the first trimester between
40 and 100 U / ml [16], [14]. Starting with the second trimester of
pregnancy, there is a decrease reaching the values of a healthy
nonpregnant woman 15 - 35 U / ml which are maintained until the end of
the pregnancy [14], [15].
HE4 (Human Epididymis protein 4)
A tumor marker of specific importance that can be detected physiologically
in insignificant amounts in trachea, pancreas, in the normal tissues of the
ovary, fallopian tube, endocervix [17], [12].
Pregnancy has no impact on HE-4, being useful in doubtful cases of ovarian
tumors in pregnant women [2].
Elevated levels of this tumor marker have been detected in most cases of
serous and endometrioid ovarian adenocarcinoma, in cases of ovarian
clear cell cancer and less frequently in the case of ovarian mucinous
adenocarcinoma [11], [5].
ROMA index - includes two serological variables, namely the values of
tumor markers CA-125 and HE4.
Morphopathological study with histological examination:
Basic diagnostic method is widely accepted and empowered with the right to
state the final decision regarding the tumor substrate and the type of
tissue.
It offers the possibility to choose a complementary method of targeted
postoperative treatment, especially for oncological pathologies.
This relatively inexpensive method provides valuable data on the
reversibility or not of the morphofunctional integrity of the organ, after
removing the vulnerable factor.
The analysis and systematization of the data obtained from the
morphopathological and histological examination can generate objective
conclusions that would be the basis of the argument of radical surgery
without remorse regarding the preservation of functionally depleted
tissues by dystrophic mechanisms.
At the same time, it can bring solid arguments in favor of organo-
preservation surgery when whole morphofunctional units are discovered
in the remaining tissue after the removal of the vulnerable factor.
Conclusions
The ROMA algorithm suggests prognostic confidence, analyzing its sensitivity and specificity according to
the results of our study.
It can serve as an essential argument for triage pregnant women with ovarian masses in the context of
personalized approach and choice of pregnancy management.
The assessment of tumor risk through the ROMA algorithm is simple and can be easily implemented in
daily practice in order to complement the diagnostic methods used at the stage of choosing personalized
treatment.
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Fig. Assessment of potential tumor risk using the ROMA index through 
the Adnexal Mass Risk Prediction Models platform
Introduction
According to literature data the incidence of ovarian cysts during pregnancy ranges
from 0.15 to 5.7% [1],[7],[13].
Of the total number of ovarian tumors detected during pregnancy, the incidence of
those with malignant potential varies within the limits of 0.8 - 13% [4].
It is important to emphasize that malignant ovarian tumors are among the top five
cancers detected during pregnancy [9], [6]. Their low incidence incriminates the
pathology an incognito status for most of practitioners by creating difficulties in
adopting a rational conduct of both pregnancy and birth for these patients.
The vast majority of ovarian tumors in pregnant women are detected in the first or
second trimester of pregnancy, of which 65-80% are usually asymptomatic and
regress spontaneously by 14 weeks of gestation[8].
In order to prevent complications related to ovarian tumors during pregnancy such as
ovarian torsion, rupture of the ovarian cyst with acute abdomen, obstruction of the
birth pathways, and last but not least, tumor malignancy, persistent ovarian tumors
in the second trimester of pregnancy are usually resolved surgical [3], [10].
The incidence of ovarian cysts detected during pregnancy varies considerably in
different researchers reports.
Most of them are functional cysts that usually reabsorb spontaneously up to 14 weeks
of gestation and that generate an illusory shadow for practitioners, underestimating
a considerable percentage of tumors with aggressive potential.
Using imaging tools, clinical data, tumor markers in combination with logistic tools
for calculating aggressive tumor potential through the Adnexal Mass Risk
Prediction Models platform, is essential for risk stratification, making a prognosis







Fig. The structure of ovarian tumors and tumor risk in our study
Cystadenomas n= 10 - 38%
(ROMA - low)
Ovarian teratomas n=5 - 19%
(ROMA - low)
Functional cysts  n=4 - 16%
(ROMA - low)
Endometrial cysts  n=3 -12%
(ROMA - low)








n=1 - 3% (ROMA - high)
Fig.    a - malignant ovarian tumor; 
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